

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

<p>Dr. Bu Su has been appointed as a non-executive director of the Company with effect from 8 August 2024.</p>
--

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Bu Su (“**Dr. Bu**”) has been appointed as a non-executive director of the Company (“**NED**”) with effect from 8 August 2024.

Dr. Bu, aged 52, has more than 20 years of experience in the fields of molecular biomedicine and bioengineering. Prior to joining the Group, Dr. Bu has served as an associate professor in the College of Life Sciences (formerly known as College of Biology and the Environment) at Nanjing Forestry University in the People’s Republic of China since April 2014. Her research topics include genome mining, expression, directed evolution, biochemical function identification and industrial application of bioenergy enzymes and food enzymes and medical mushrooms and plant-based active substances for the development of antiobesity products to improve and prevent metabolic diseases such as obesity and diabetes. Prior to joining Nanjing Forestry University, Dr. Bu worked as a researcher at Amano Enzyme Inc., which is an enzyme production, research and development company in Japan from 1998 to 2001. Dr. Bu also worked as a postdoctoral scholar at the University of Alabama at Birmingham in the United States of America of from January 2005 to September 2009 and a research associate from January 2011 to January 2014, during which she mainly conducted research in the biomedical field related to human diseases.

Dr. Bu obtained a Doctor of Philosophy degree of Biochemistry from the Chinese University of Hong Kong in December 2004.

Dr. Bu has entered into an appointment letter with the Company for an initial term of three years commencing from 8 August 2024 and will continue thereafter until terminated by either party serving not less than one month’s written notice to the other party. Pursuant to the appointment letter, Dr. Bu is entitled to a director’s emolument of HK\$240,000 per annum. Such fee is determined by the Board based on the recommendation of the remuneration committee with reference to her experience, responsibilities, workload and time devoted to the Company and will be subject to review by the remuneration committee of the Company from time to time. Save as disclosed above, Dr. Bu is not expected to receive any other remuneration for holding her office as a NED.

In accordance with the articles of association of the Company, Dr. Bu will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Dr. Bu will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Save as disclosed above, as at the date of this announcement, Dr. Bu (i) does not hold any other position in the Company and other members of the Group; (ii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not possess any other major appointments or professional qualifications; (iv) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any information which is disclosable nor is/was Dr. Bu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited and there are no other matters concerning Dr. Bu that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Dr. Bu for joining the Board.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 8 August 2024

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; the Non-executive Director is Dr. Bu Su; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Ms. Chow Ching Man.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.